Cepheid makes second diagnostic acquisition.
Cepheid continues to expand its molecular diagnostics PCR business. Last year, the company purchased Actigenics (see IBO 8/15/06), which provides mRNAs. For the first nine months of 2006, the Cepheid's clinical molecular diagnostics market accounted for 22% of sales, or $13.4 million, up from 10% of sales the year before.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Executive Briefing: News, Trends & Market Intelligence for Instrument Executives|
|Publication:||Instrument Business Outlook|
|Date:||Feb 15, 2007|
|Previous Article:||Thermo Fisher requests approval to sell Genevac to Riverlake.|
|Next Article:||BioWisdom and OmniViz merge.|